See the development of manufacturer's prices and yearly therapy costs of all products with negotiated reimbursement prices. more >>
- AMNOG monitor Information · Analysis · Research (389 KB)
Identify decision-paths and trends in early benefit assessment. The AMNOG monitor is indispensable for managers and decision-makers in market access, pricing and reimbursement.
Resolutions December 2021
|Dostarlimab||Jemperli®||Endometrial carcinoma (EC), after platinum-based therapy||100% no additional benefit|
|Tagraxofusp||Elzonris®||Blastic plasmacytoid dendritic cell neoplasm (BPDCN), first-line||100% Hint for non-quantifiable additional benefit|
|Venetoclax (5)||Venclyxto®||Acute myeloid leukaemia (AML), combination therapy, first-line||100% Hint for considerable additional benefit|
|Berotralstat||Orladeyo®||Hereditary angioedema (HAE), prophylaxis, ≥ 12 years||100% no additional benefit|
|Ponesimod||Ponvory®||Relapsing multiple sclerosis (MS)||100% no additional benefit|
Dear readers of the AMNOG Monitor,
During the weeks since the federal election and in view of low vaccination rates, politicians have failed to prepare the population for the consequences of the 4th wave of the Corona pandemic. The traffic light coalition is now about to conclude coalition negotiations. The Health and Care working group (AG Gesundheit und Pflege) has already presented its draft statement on 18 Nov 2021. In addition to vague formulations such as further developing the AMNOG, reforming of the G-BA and ensuring the supply of innovative medicines and vaccines, the paper specifies:
- An increase of the manufacturer's rebate for patent-protected medicinal products to 16% (up from 7%)
- Continuation of the price moratorium
- Reimbursement prices valid from the 7th month after market launch (previously 13th month).
- Reduction of VAT for medicinal products from 19% to 7%
The European Council has adopted the Regulation on Health Technology Assessments (EU-HTA) on 9 November 2021. The legislative process, which had been initiated by the Commission in 2018, is nearing completion. Adoption by the European Parliament is expected in December 2021.
In November, 19 new early benefit assessment resolutions were adopted (cf. table). At the same time, the G-BA adopted a new framework guideline for minimum quality-assurance requirements for gene and cell therapies (ATMP). https://www.g-ba.de/presse/pressemitteilungen-meldungen/994/
The evaluation of Onasemnogen-Abeparvovec (Zolgensma®) for the treatment of spinal muscular atrophy (SMA) was eagerly awaited. In this assessment, the €50 million threshold was reached before the initial benefit assessment was completed, so that the manufacturer was required to provide a full dossier with a comparison to an appropriate comparative therapy which the G-BA has specified as Spinraza®. The G-BA did see no additional benefit for Onasemnogen-Abeparvovec in any of the patient groups. New data based on the first collection of routine practice data (AbD) are expected to be available in summer 2027. Professor Hecken, the chairman of the G-BA, expressly emphasized that this does not mean a restriction of application. The costs for a single patient exceeds 2 million euros.